iiinova — where your digital self keeps evolving

Reposted by Elisabetta Bonzano MD, PhD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 26/05/2026

The OncoAlert🚨 Lung faculty’s TOP 10 abstracts In Thoracic🫁 Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior #LungCancer experts across #NSCLC & #SCLC . A snapshot of what will shape LUNG oncology at #ASCO26 👇

021

Reposted by Elisabetta Bonzano MD, PhD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 25/05/2026

We are getting Closer #OncoAlert5k 🏃‍♂️‍➡️ at #ASCO26 Are you Ready?? Join US!!! May 30th, 2026 7am SIGN UP HERE 👉 buff.ly/3kvnMej

031

Reposted by Elisabetta Bonzano MD, PhD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 25/05/2026

The OncoAlert🚨 GU faculty’s TOP 10 abstracts In GU Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior GU cancer experts across #ProstateCancer #KidneyCancer #BladderCancer . A snapshot of what will shape GU oncology at #ASCO26

034

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 25/03/2026

📌 Advances in targeted therapies Excellent presentation on CDK4/6 ✨ by prof Nadia Harbeck ✨at #EBCC15 @oncoalert.bsky.social #OncoAlertAF

120

Reposted by Elisabetta Bonzano MD, PhD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 23/03/2026

🌐 Big news: The 6th OncoAlert 🚨Colloquium is NOW AVAILABLE IN YOUR LANGUAGE!! ALL VIDEOS HERE 👇👇https://oncoalert360.com/multi-language127760colloquium.html 🇪🇸🇮🇳🇵🇹🇮🇹🇫🇷🇺🇦🇯🇵🇲🇽🇸🇦🇷🇺and many more SPOKEN & WITH CAPTIONS in 1⃣8⃣Languages Top oncology experts. Global reach. Zero barriers.

121

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 19/10/2025

📌 Primary Results From ASCENT-03 ✨ PFS: 9.7 mo vs 6.9 mo, HR 0.62 ORR: 48% vs 46% DOR: 12.2 vs 7.2 mo OS immature: HR 0.98 PFS2: 18.2 vs 14.0, HR 0.70 Dr. @Javier Cortès at Proffered paper session 2 #ESMO25 🇩🇪 📍Berlin @oncoalert.bsky.social #OncoalertAF @nejm.org 🔗 lnkd.in/diBhSjXG

020

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 19/10/2025

📌 Primary results from the randomised, phase III TROPION-Breast02 trial✨ 🔸OS HR 0.79 (95% Cl 0.64-0.98); P=0.0291 🔹PFS by BICR HR 0.57 (95% CI 0.47-0.69); Р<0.0001 🔸 ≥5-month improvement in both median OS and PFS Proffered paper session 2 #ESMO25 @oncoalert.bsky.social #OncoalertAF

021

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 05/06/2025

📌 Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy 🔗nejm.org/doi/full/10.10… 👉🏻 Results of NRG-NSABP B-51/RTOG 1304❗️ RNI vs no RNI in ypN0 after neoadjuvant chemo (cT1-T3N1) @oncoalert.bsky.social #OncoAlertAF #BreastCancer #RadOnc

032

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 03/06/2025

📌 Opting Out of Therapy for Early-Stage Breast Cancer: How Far Might We Go? ✨Prof @icromeattini.bsky.social 👉🏻 How to Integrate Radiotherapy Into Current Treatment Concepts❗️ @oncoalert.bsky.social #OncoAlertAF #ASCO25 #RadOnc

053

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 03/06/2025

📌 NRG-BR003: A randomized phase Ill trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBC. ✨Vicente Valero #ASCO25 @oncoalert.bsky.social #OncoAlertAF

021

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 03/06/2025

📌 The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/ HER2- breast cancer. ✨Erica L. Mayer, MD, MPH, FASCO ✔️Rapid Oral Abstract Session Breast Cancer-Local/Regional/ Adjuvant @oncoalert.bsky.social #OncoAlertAF #ASCO25 #Day3

011

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 03/06/2025

📌 Highlights of the Day II 👉🏻Breast Cancer-Metastatic ✨@maryam_lustberg 👏🏻 🟩 Key takeaways HR+ MBC 🟦 Key takeaways in HER2 positive MBC 🟨 Key Takeaways Metastatic TNBC @oncoalert.bsky.social #OncoAlertAF #ASCO25

011

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 03/06/2025

📌 Do We "Node" What to Do About the Axilla❓ Great discussion👏🏻 ✨Mediget Teshome, MD, FACS, MPH @oncoalert.bsky.social #OncoAlertAF #ASCO25

000

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 03/06/2025

📌 LBA Session❗️ ✨DESTINY-Breast09 results ✅ Stunning presentation ✨ @stolaney1.bsky.social 👏🏻 👉🏻 Median PFS: 🔸T-DXd + P: 40.7 mo 🔸THP: 26.9 mo HR 0.56, p<0.001 👉🏻ORR 85.1% @oncoalert.bsky.social #OncoAlertAF #ASCO25

000

Reposted by Elisabetta Bonzano MD, PhD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 30/05/2025

The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸 @elisaagostinetto.bsky.social ‬ @erikahamilton9.bsky.social ‬ @drsgraff.bsky.social ‬ @elisabettabonzano.bsky.social ‬

031

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 03/05/2025

📌Great discussant #ESTRO25 prof @icromeattini.bsky.social 👏🏻👏🏻 ✨ Late-Breaking Papers ✨ 👉🏻10y FAST-Forward randomised trial 👉🏻 DBCG Skagen trial 1 @oncoalert.bsky.social

073

Reposted by Elisabetta Bonzano MD, PhD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 21/04/2025

A Great Presentation by Dr. Hope Rugo 🇺🇸 on Advanced Triple Negative #BreastCancer 🚨 vimeo.com/1077243852?s... Get caught up on the TOP trials and those that impacted Clinical Practice in less than 2⃣0⃣min You Can find ALL video here, Free & On Demand👇 oncoalert360.com/oncoalert128...

033

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 19/04/2025

📌Proud to share our latest review: “Current Treatment Paradigms for Advanced Melanoma with Brain Metastases” 🧠 mdpi.com/1422-0067/26/8… 👉🏻 Optimizing local & systemic strategies, tackling key clinical questions, and paving the way for tailored therapies. @oncoalert.bsky.social #OncoAlertAF

011

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 12/04/2025

The @oncoalert.bsky.social 🚨Weekly Round Up Covering the TOP of the week April 4-10, 2025 REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa... youtu.be/l_jcTe69cCs

oncoalert360.com

THE ONCOALERT NETWORK

Welcome to OncoAlert

022

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 30/03/2025

📌 Awareness of genomic testing among patients with breast cancer in Europe 🧬 www.sciencedirect.com/science/arti... @oncoalert.bsky.social #OncoAlertAF @breastdocuk.bsky.social @csabadegi.bsky.social

111

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 29/03/2025

📌 Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial @oncoalert.bsky.social #OncoAlertAF thegreenjournal.com/article/S0167-…

011

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 28/03/2025

📌 Selective Elimination of Breast Surgery for Invasive Breast Cancer A Nonrandomized Clinical Trial jamanetwork.com/journals/jam... @oncoalert.bsky.social

011

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 28/03/2025

📌 Incidence and Risk Factors of Interval and Screen-Detected Breast Cancer jamanetwork.com/journals/jam... @oncoalert.bsky.social

011

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 28/03/2025

📌 Small extracellular vesicles and particles (sEVPs) derived from tumor-free pre-metastatic organs promote breast cancer metastasis and support organotropism molecularcancer.biomedcentral.com/articles/10.11… @oncoalert.bsky.social

031

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 28/03/2025

📌 Smoking increases breast toxicity despite adjuvant hypofractionated IMRT in early breast cancer 👉🏻 addressing lifestyle factors to improve patient outcomes and quality of life 🚭 ro-journal.biomedcentral.com/articles/10.11… @oncoalert.bsky.social

000

Reposted by Elisabetta Bonzano MD, PhD

VJOncology @vjoncology.bsky.social · 25/03/2025

🚨New #VJOncoAlertJournalClub! with @oncoalert.bsky.social 🗞️ Breaking down the latest in #oncology – every week! Join Misty Shields as she shares the latest advances in #SCLC, including the game-changing #ADRIATIC trial, DLL3-targeting therapies & more www.vjoncology.com/video/ayudqc...

tinyurl.com

Top Advances in SCLC

In this latest episode of the VJOncoAlert Journal Club, Misty Shields, MD, PhD, Indiana University Simon Comprehensive Cancer Center, Indianapolis,...

022

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 27/03/2025

📌 Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation sciencedirect.com/science/articl… @oncoalert.bsky.social #OncoAlertAF

011

Reposted by Elisabetta Bonzano MD, PhD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 20/03/2025

Development of a prediction model for ctDNA detection (Cir-Predict) in #BreastCancer buff.ly/6Ixw2Jy This study developed a prediction model, Cir-Predict, to assess the detectability of circulating tumor DNA (ctDNA) in breast cancer patients

073

Reposted by Elisabetta Bonzano MD, PhD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 20/03/2025

Effect of BMI on #BreastCancer stage and #BreastCancer specific survival link.springer.com/article/10.1... Findings highlight the need for more comprehensive assessments of body composition and metabolic health in BC patients. @elisaagostinetto.bsky.social @elisabettabonzano.bsky.social

0105

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 19/03/2025

📌 Toxicity and Efficacy of Different Target Volume Delineations of Radiation Therapy Based on the Updated RTOG/NRG and EORTC Guidelines in Patients With Grade 3-4 Glioma: A Randomized Controlled Clinical Trial redjournal.org/article/S0360-… @oncoalert.bsky.social

132

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 14/03/2025

Oncology HERE & NOW Webcast/Podcast Now Out, JOIN OncoAlert Faulty🚨 Dr. @elisaagostinetto.bsky.social 🇧🇪& Dr. @maryamlustberg.bsky.social 🇺🇸 as they dive into #BreastCancer and the use of adj CDK 4/6 inhibitors and more youtu.be/zw8vYd894jI Podcasts : buzzsprout.com/1324033/epis...

youtu.be

Oncology Here & Now Podcast: Breast Cancer with Dr. Maryam Lustberg & Dr. Elisa Agostinetto

YouTube video by OncoAlert 360

054

Reposted by Elisabetta Bonzano MD, PhD

Elisa Agostinetto @elisaagostinetto.bsky.social · 14/03/2025

Now out a new episode of Oncology Here&Now, a podcast by @oncoalert.bsky.social 🎙️ I had the pleasure to discuss with @maryamlustberg.bsky.social about adjuvant CDK4/6i, including: 🔸how to choose between abema and ribo 🔸how to manage progression during or after adj CDK4/6i 🔸Male breast cancer!

buff.ly

Dr. Maryam Lustberg & Dr. Elisa Agostinetto discuss CDK4/6 inh in Breast cancer - OncoAlert

Oncology Here & NowIn this interview, Dr. Elisa Agostinetto from the Jules Bordet Institute in Belgium speaks with Dr. Maryam Lustberg from Yale Cancer Center. Together, they dive deep into the us...

021

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 27/02/2025

📌Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Phase III trial @oncoalert.bsky.social

011

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 27/02/2025

📌 Comparison of 18F-FET-PET- and MRI-based target definition for re-irradiation treatment of recurrent diffuse glioma 🧠 sciencedirect.com/science/articl… @oncoalert.bsky.social

021

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 23/02/2025

📌 Pre-Operative Single Fraction Stereotactic Partial Breast Irradiation (S-PBI) for Early-Stage Breast Cancer Patients with Gammapod Technology: Pathological Findings and Ki-67 Evaluation redjournal.org/article/S0360-… @oncoalert.bsky.social

032

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 09/02/2025

📌 Long-Term Outcomes of Radiation Monotherapy Versus Combined Radiation Monotherapy + Hormone Therapy in Low-Risk Early-Stage Breast Cancer Patients 70 Years or Older After Breast-Conserving Surgery @oncoalert.bsky.social #OncoAlertAF @ijrobp.bsky.social #BreastCancer

022

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 06/02/2025

📌 Whole genome sequencing powered ctDNA sequencing for breast cancer detection annalsofoncology.org/article/S0923-… @oncoalert.bsky.social

011

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 06/02/2025

Day Three #OncoAlertColloquium 🚨 #BreastCancer REGISTER for FREE HERE👉 buff.ly/42IcWl2 Fatima Cardoso 🇵🇹 👏🏻 of @ABCGlobalAll Covering Brain Metastasis in Breast Cancer: Year in Review @oncoalert.bsky.social

021

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 06/02/2025

Day Three #OncoAlertColloquium 🚨 #BreastCancer REGISTER for FREE HERE👉 buff.ly/4gsEa2f prof @icromeattini.bsky.social 🇮🇹 👏🏻 Radiation Oncology in Breast Cancer: Year in Review @oncoalert.bsky.social

042

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 05/02/2025

Day Three #OncoAlertColloquium 🚨 #BreastCancer REGISTER for FREE HERE👉 buff.ly/4hnnLgR prof @matteolambe 👏 @SanMartino_Ge @Unige Covering Fertility Preservation- Breast Cancer: Year in Review @oncoalert.bsky.social

022

Reposted by Elisabetta Bonzano MD, PhD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 05/02/2025

Day3⃣ #OncoAlertColloquium 🚨 #BreastCancer REGISTER for FREE HERE👉 buff.ly/40XzdKp @E_de_Azambuja 🇧🇪 of @JulesBordet Covering Early HER2+ Breast Cancer: Year in Review REGISTER NOW for a Live chat with Dr. de Azambuja

021